Kymera Therapeutics Stock Forecast

Stock Price Forecast

According to 23 analysts polled by S&P Global, Kymera Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $119.19. The average 1-year stock price forecast is 31.80% higher than the current stock price, while the lowest is $97 (+7.27%) and the highest is $140 (+54.82%).

Price Target: $119.19 (+31.80%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$97	$119.19	$119	$140
Change	+7.27%	+31.80%	+31.59%	+54.82%

Analyst Ratings

The average analyst rating for Kymera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	17	17	17	17	18	17
Buy	5	5	5	5	5	5
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	23	23	23	23	24	23

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Brian Cheng J.P. Morgan	J.P. Morgan	Buy Maintains $120	Buy	Maintains	$120	+32.70%	Jun 16, 2026
Judah Frommer Morgan Stanley	Morgan Stanley	Buy Maintains $123 → $119	Buy	Maintains	$123 → $119	+31.59%	Jun 10, 2026
Tazeen Ahmad Bank of America Securities	Bank of America Securities	Buy Reiterates $110	Buy	Reiterates	$110	+21.64%	Jun 9, 2026
Edward Nash Canaccord Genuity	Canaccord Genuity	Buy Maintains $106	Buy	Maintains	$106	+17.22%	Jun 2, 2026
Marc Frahm TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 6, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

84.48M

from 39.21M

115.44%

from 39.21M

Revenue Next Year

41.02M

from 84.48M

-51.45%

from 84.48M

EPS This Year

-3.52

from -3.69

EPS Next Year

-4.35

from -3.52

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	72.83M	46.83M	78.59M	47.07M	39.21M	84.48M
Revenue Growth	114.00%	-35.71%	67.84%	-40.11%	-16.70%	115.44%
Gross Profit	-64.19M	-117.42M	-110.49M	-193.18M	-277.36M	84.48M
Gross Margin	-88.13%	-250.76%	-140.59%	-410.38%	-707.34%	100.00%
Operating Income	-100.53M	-161.26M	-165.53M	-256.71M	-345.54M	-390.32M
Net Income	-100.22M	-154.81M	-146.96M	-223.86M	-311.35M	-341.09M
EPS	-	-	-	-	-3.69	-3.52
Free Cash Flow	-58.30M	-90.21M	-97.62M	-126.83M	-136.04M	-317.91M
No. Analysts	-	-	-	-	-	21

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	124.4M
Avg	84.5M
Low	41.7M

Revenue Growth

Revenue Growth	2026	2027	2028
High	217.2%
Avg	115.4%
Low	6.3%

EPS Forecast

EPS	2026	2027	2028
High	-2.64
Avg	-3.52
Low	-5.51

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-